We demonstrate that the use of gemcitabine and TRAIL enhances the inhibition of survival of pancreatic cancer cells and provide data to show that both the extent of dephosphorylation and the level of total 4E-BP1 are strongly increased as a result of the combination treatment. This evidence concerns the gene EIF4EBP1 and pancreatic neoplasm.